Panthera Biopartners has again broadened the range of therapy areas it can run clinical trials in to include not only vaccines, cardiovascular, general medicine, diabetes, neurology, respiratory, dermatology and rheumatology but also specialist areas such as oncology, NASH and early dementia trials. The ability to carry out trials with specialist PIs (principal investigators) will attract more trials to the UK particularly as the UK is seen as an attractive destination due to the quality of specialists and its diverse and dense population.
Since it was founded in 2019 by Dr Ian Smith who founded Synexus, and Professor John Lyon – a past global VP of CRO Covance, Panthera has become the largest SMO in the UK, running clinical trials on behalf of 10 out of the top 12 pharma companies and all of the top five CROs across a broad range of therapies.
Stuart Young, CEO of Panthera, commented, “We continue to not only expand our network of sites but also to broaden the conditions for which we can run clinical trials. Founded by Dr Ian Smith, who built Synexus into the largest SMO in the world, we have refined his original model and incorporated more sophisticated outreach strategies to recruit patients, which, in many cases, exceed what we have promised to our pharma and CRO clients. This success has led to demand from our clients to move into more specialist areas where historically they have experienced poor recruitment where we have been able to meet, and often exceed, their targets.”
Panthera has in the last two years been the top recruiter globally in four studies, the top recruiter in the UK on six other studies and has achieved first patient in globally or in the UK on nine studies.
Panthera’s expanding UK network of dedicated clinical trial sites includes clinics in Glasgow, York, Sheffield, Preston, Rochdale and Enfield.